Citation: W. Kalow et al., HYPOTHESIS - COMPARISONS OF INTERINDIVIDUAL AND INTRAINDIVIDUAL VARIATIONS CAN SUBSTITUTE FOR TWIN STUDIES IN DRUG RESEARCH, Pharmacogenetics, 8(4), 1998, pp. 283-289
Authors:
FONTANA RJ
DEVRIES TM
WOOLF TF
KNAPP MJ
BROWN AS
KAMINSKY LS
TANG BK
FOSTER NL
BROWN RR
WATKINS PB
Citation: Rj. Fontana et al., CAFFEINE BASED MEASURES OF CYP1A2 ACTIVITY CORRELATE WITH ORAL CLEARANCE OF TACRINE IN PATIENTS WITH ALZHEIMERS-DISEASE, British journal of clinical pharmacology, 46(3), 1998, pp. 221-228
Citation: W. Li et al., REGULATION OF CYTOCHROME-P450 ENZYMES BY ARYL-HYDROCARBON RECEPTOR INHUMAN-CELLS - CYP1A2 EXPRESSION IN THE LS180 COLON-CARCINOMA CELL-LINE AFTER TREATMENT WITH 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN OR 3-METHYLCHOLANTHRENE, Biochemical pharmacology, 56(5), 1998, pp. 599-612
Citation: P. Radypentek et al., INTERINDIVIDUAL VARIATION IN THE ENZYMATIC 15-KETO-REDUCTION OF 13,14-DIHYDRO-15-KETO-PROSTAGLANDIN E-1 IN HUMAN LIVER AND IN HUMAN ERYTHROCYTES, European Journal of Clinical Pharmacology, 52(2), 1997, pp. 147-153
Authors:
PASTRAKULJIC A
TANG BK
ROBERTS EA
KALOW W
Citation: A. Pastrakuljic et al., DISTINCTION OF CYP1A1 AND CYP1A2 ACTIVITY BY SELECTIVE-INHIBITION USING FLUVOXAMINE AND ISOSAFROLE, Biochemical pharmacology, 53(4), 1997, pp. 531-538
Citation: Bk. Tang et W. Kalow, ANALYSIS OF WITHIN-SUBJECT VARIATION OF CAFFEINE METABOLISM WHEN USEDTO DETERMINE CYTOCHROME P4501A2 AND N-ACETYLTRANSFERASE-2 ACTIVITIES, Cancer epidemiology, biomarkers & prevention, 5(3), 1996, pp. 231-231
Authors:
BUTERS JTM
TANG BK
PINEAU T
GELBOIN HV
KIMURA S
GONZALEZ FJ
Citation: Jtm. Buters et al., ROLE OF CYP1A2 IN CAFFEINE PHARMACOKINETICS AND METABOLISM - STUDIES USING MICE DEFICIENT IN CYP1A2, Pharmacogenetics, 6(4), 1996, pp. 291-296
Citation: G. Appanna et al., A SENSITIVE METHOD FOR DETERMINATION OF CYTOCHROME P4502D6 ACTIVITY IN-VITRO USING BUPRANOLOL AS SUBSTRATE, Drug metabolism and disposition, 24(3), 1996, pp. 303-306
Citation: M. Patel et al., INTERINDIVIDUAL VARIABILITY IN THE GLUCURONIDATION OF (S)-OXAZEPAM CONTRASTED WITH THAT OF (R)-OXAZEPAM, Pharmacogenetics, 5(5), 1995, pp. 287-297
Citation: M. Patel et al., (S)OXAZEPAM GLUCURONIDATION IS INHIBITED BY KETOPROFEN AND OTHER SUBSTRATES OF UGT2B7, Pharmacogenetics, 5(1), 1995, pp. 43-49
Citation: Bk. Tang et W. Kalow, VARIABLE ACTIVATION OF LOVASTATIN BY HYDROLYTIC ENZYMES IN HUMAN PLASMA AND LIVER, European Journal of Clinical Pharmacology, 47(5), 1995, pp. 449-451
Authors:
MASIMIREMBWA CM
BEKE M
HASLER JA
TANG BK
KALOW W
Citation: Cm. Masimirembwa et al., LOW CYP1A2 ACTIVITY IN RURAL SHONA CHILDREN OF ZIMBABWE, Clinical pharmacology and therapeutics, 57(1), 1995, pp. 25-31
Citation: Bk. Tang et al., CAFFEINE AS A PROBE FOR CYP1A2 ACTIVITY - POTENTIAL INFLUENCE OF RENAL FACTORS ON URINARY PHENOTYPIC TRAIT MEASUREMENTS, Pharmacogenetics, 4(3), 1994, pp. 117-124
Authors:
ROBERTS EA
KOHNO Y
PASTRALKULJIC A
TANG BK
KALOW W
Citation: Ea. Roberts et al., PHENACETIN O-DEETHYLASE IN NOVEL HUMAN HEPATOCYTE LINES - EVIDENCE FOR PRESERVATION OF BASAL AND INDUCIBLE CYP1A2 IN-VITRO, Hepatology, 20(4), 1994, pp. 10000187-10000187
Citation: Ea. Roberts et al., CAFFEINE BIOTRANSFORMATION IN HUMAN HEPATOCYTE LINES DERIVED FROM NORMAL LIVER-TISSUE, Biochemical and biophysical research communications, 201(2), 1994, pp. 559-566
Citation: W. Kalow et Bk. Tang, THE USE OF CAFFEINE FOR ENZYME ASSAYS - A CRITICAL-APPRAISAL, Clinical pharmacology and therapeutics, 53(5), 1993, pp. 503-514